
Opinion|Videos|March 22, 2024
Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies
Virginia Kaklamani, MD, DSc, explores strategies for mitigating fatigue, nausea, vomiting, and other toxicities and adverse events that may arise when patients receive endocrine therapy in combination with CDK4/6 inhibitors.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement





















